Principal Investigator: Lorcan McGarvey                                           

Name of the Study: AXALBION

Why is this Study important?

Chronic cough is a disease with significant unmet needs. AX-8 showed promising results with reduction in cough frequency, particularly in patients experiencing the greatest throat discomfort, a distressing symptom observed in most chronic cough patients.

What is the Research question/aim?:

The primary objective is to evaluate the effect of AX-8 in reducing cough frequency in participants with throat discomfort, or refractory or unexplained chronic cough (RCC/UCC).

What the Study involves:

Participants will be given AX-8 40mg or a matching placebo three times a day at intervals of four hours over two weeks. This will be followed by a seven-day washout period before switching to the opposite treatment for another two weeks.

Who can take part in the Study?

People aged between 18 and 80 years of age who have a diagnosis of RCC/UCC for at least one year and associated upper airway symptoms (throat or laryngeal irritation, tickling, dryness or discomfort) of at least 8-week duration.

Contact Information:

Áine Redfern-Walsh– Research Nurse    Aine.RedfernWalsh@belfasttrust.hscni.net 

Northern Ireland Clinical Research Facility (NICRF)

U Floor, Belfast City Hospital

51 Lisburn Road

Belfast BT9 7AB